Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma

MLA

Shoya Ono, et al. “Trametinib Improves Treg Selectivity of Anti-CCR4 Antibody by Regulating CCR4 Expression in CTLs in Oral Squamous Cell Carcinoma.” Scientific Reports, vol. 12, no. 1, Dec. 2022, pp. 1–13. EBSCOhost, https://doi.org/10.1038/s41598-022-22773-1.

APA

Shoya Ono, Susumu Suzuki, Yutaro Kondo, Ikuko Okubo, Mitsuo Goto, Tetsuya Ogawa, Hidefumi Kato, Hideaki Ito, Taishi Takahara, Akira Satou, Toyonori Tsuzuki, Kazuhiro Yoshikawa, Toru Nagao, & Ryuzo Ueda. (2022). Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma. Scientific Reports, 12(1), 1–13. https://doi.org/10.1038/s41598-022-22773-1

Chicago

Shoya Ono, Susumu Suzuki, Yutaro Kondo, Ikuko Okubo, Mitsuo Goto, Tetsuya Ogawa, Hidefumi Kato, et al. 2022. “Trametinib Improves Treg Selectivity of Anti-CCR4 Antibody by Regulating CCR4 Expression in CTLs in Oral Squamous Cell Carcinoma.” Scientific Reports 12 (1): 1–13. doi:10.1038/s41598-022-22773-1.